LVH mediated 7.4%, 11.2%, and 21.9% of the effect of FGF-23 on all-cause mortality, AF, and CHF, respectively.<h4>Conclusions</h4>In CKD patients, FGF-23 had a minor effect on the development of long-term adverse outcomes through LVH. This evidence concerns the gene FGF23 and atrial fibrillation.